Baidu
map

EASD 2016:新发糖尿病?警惕胰腺癌!

2016-09-16 Mechront 译 MedSci原创

第52届欧洲糖尿病学会年会(EASD 2016)称:对新发糖尿病患者进行胰腺癌的筛查,对于胰腺癌的早期诊断和早期治疗可能还是有效性。 来自布拉格查尔斯特大学医学院内分泌的Pavel Škrha博士及其同事,对60名(平均年龄67岁)胰腺癌+糖尿病成人患者,以及34名(平均年龄63岁)2型糖尿病患者(没有胰腺癌),还有30名对照(平均年龄63岁)进行了研究,比较生化标志物癌抗原(CA)19-9

第52届欧洲糖尿病学会年会(EASD 2016)称:对新发糖尿病患者进行胰腺癌筛查,对于胰腺癌的早期诊断和早期治疗可能还是有效性。

来自布拉格查尔斯特大学医学院内分泌的Pavel Škrha博士及其同事,对60名(平均年龄67岁)胰腺癌+糖尿病成人患者,以及34名(平均年龄63岁)2型糖尿病患者(没有胰腺癌),还有30名对照(平均年龄63岁)进行了研究,比较生化标志物癌抗原(CA)19-9单独或联合microRNA-196和microRNA-200时,识别胰腺癌患者的灵敏度和特异性。

根据活检或手术切除肿瘤,识别胰腺癌诊断;根据美国糖尿病协会标准,诊断糖尿病或前驱糖尿病。

胰腺癌患者中,44名为新发糖尿病,16名有长期糖尿病。这表明,胰腺癌和新发糖尿病的关联性,比胰腺癌与长期糖尿病的关联性更强。

胰腺癌患者,CA 19-9、microRNA-196和microRNA-200,这三种标志物含量都升高(所有P < .0001)。当单独使用CA 19-9时,敏感性和特异性分别为85%和73%;三个指标一起使用时,敏感性和特异性分别为95%和77%。

作者认为,胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过来,新发糖尿病作为胰腺癌的筛查之一,同时,糖尿病的出现是否会恶化病情?等等一系列问题,还需要未来进一步的研究。

原始出处:

krha P, et al. Poster 572. Presented at: 52nd EASD Annual Meeting; Sept. 12-16, 2016; Munich.

New-onset diabetes may signal pancreatic cancer.Healio.September 15, 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2017-08-08 okhuali
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-22 1e10c84am36(暂无匿称)

    文章很好,非常有益

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-17 qilu_qi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-17 lhl629

    很好的内容,继续学习。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 lhl629

    学习了,很好。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 刘煜

    谢谢学习了。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 知难而进

    谢谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 知难而进

    继续关注!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 知难而进

    胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1690601, encodeId=465916906015e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Tue Aug 08 19:37:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132821, encodeId=e588132821fe, content=文章很好,非常有益, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 22 09:06:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534092, encodeId=c8f11534092bd, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Sat Sep 17 23:37:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129080, encodeId=07de12908062, content=很好的内容,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Sat Sep 17 07:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128808, encodeId=e161128808c2, content=学习了,很好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Fri Sep 16 20:36:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128687, encodeId=67a112868e30, content=谢谢学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Sep 16 14:47:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128638, encodeId=968d128638ba, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128639, encodeId=2928128639dd, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128637, encodeId=4dcd12863ecc, content=胰腺癌患者中的新发糖尿病或前驱糖尿病检测率更高,是否可以反过, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 12:53:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128625, encodeId=d5d212862558, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Fri Sep 16 12:48:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 Guoxj3234

    学习起来

    0

相关资讯

Diabetes Care:西他列汀,是否会增加胰腺炎和胰腺癌风险?

我们对使用二肽基肽酶-4抑制剂(DPP-4I)西格列汀治疗的2型糖尿病+心血管疾病患者进行了研究,评估他们的急性胰腺炎和胰腺癌发病率。 在TECOS试验(关于西他列汀的心血管安全性研究)中,纳入了14671例参与者,中位随访3年。没有胰腺事件、急性胰腺炎或胰腺癌患者的基线差异很小。 随机接受西他列汀的参与者中,23(0.3%)名患者发生胰腺炎(安慰剂组为12[0.2%]名;HR 1.9

JCEM:肾上腺功能不全患者的代谢和精神负担很重

肾上腺功能不全(AI)(原发[PAI],继发于垂体疾病[PIT]和先天性肾上腺皮质增生症[CAH])患者的预期寿命会降低,但是为什么会这样呢?潜在的解释仍然是未知的。 我们进行了一项回顾性观察研究,评估AI患者的特征、并发症和住院情况。 研究纳入了10383名AI患者,PAI、PIT和CAH患者分别有1014名、8818名和551名。按1:1、基于年龄性别、保险和地区,匹配对照组,随访

只知道二甲双胍?这类糖尿病药或成“抗癌新成员”

9月12日,发表在PNAS杂志上的一项研究中,一个国际科学家小组发现了一种对抗NAF-1(一种与乳腺癌增殖相关的蛋白)过表达的方法。降低NAF-1的水平以及它运输的铁硫簇(iron-sulfur clusters)的活性可能是阻止肿瘤生长的关键。具体来说,研究人员发现,一种通常用于治疗2型糖尿病的药物——吡格列酮(pioglitazone)——能够有效抑制NAF-1的水平。此外,他们还发现,NAF

谷歌母公司进军糖尿病治疗领域

谷歌的母公司“字母表”旗下专注生命健康科学的子公司Verily和法国制药企业赛诺菲日前宣布联手投资5亿美元,成立一家集糖尿病治疗设备与服务于一身的合资公司。 Verily和赛诺菲发表联合声明说,新成立的公司会将Verily在微型电子、分析和消费软件开发领域的经验与赛诺菲的临床技术和经验相结合,为糖尿病患者提供创新性疗法。 糖尿病已成为全球公共卫生一个主要威胁。数据显示,全球有近4亿

糖尿病患者该如何“备孕”?

随着糖尿病的迅猛增长,我们已然进入“盛糖”时代。不少育龄期的男男女女,要么父母有糖尿病,要么配偶有糖尿病。他们最关心的是,糖尿病患者的孩子得糖尿病的几率有多大?糖尿病人什么时机适合妊娠?如何才能要个健康的宝宝?父母遗传的不是糖尿病本身,而是对糖尿病的易感性临床上见到的糖尿病绝大多数都是2型糖尿病,它是“遗传因素”和“环境因素”共同作用的结果。子女可能从糖尿病父母那里获得糖尿病的易感基因,但并不是说

六成糖尿病患者服用他汀类药物,真的可以随便吃吗?

众所周知,他汀是非常有效的降胆固醇药,这类药物通过抑制肝脏合成胆固醇,降低血液中胆固醇水平,从而降低形成动脉粥样斑块的风险,达到预防冠心病和脑血管病的目的。常见的他汀类药物包括普伐他汀、洛伐他汀、辛伐他汀、阿托伐他汀等。四成糖尿病患者未按照规定使用他汀类药物近日,《美国心脏病学会杂志》(Journal of the American College of Cardiology)报道,有2/5的未患

Baidu
map
Baidu
map
Baidu
map